Project 3: Synthesis and Optimization of Selective a4B2 nAChR Desensitizers According to the United States National Institute on Drug Abuse, abuse and addiction to alcohol, nicotine, and illegal substances cost Americans upwards of half a trillion dollars a year, considering their combined medical, economic, criminal, and social impact. Every year, abuse of illicit drugs and alcohol contributes to the death of more than 100,000 Americans, while tobacco is linked to an estimated 440,000 deaths per year. With this in mind, there is a great need to develop new therapeutics for drug abuse and addictions. In this grant we will use medicinal chemistry to design, synthesize and optimize desensitizers of a4B2 nAChR based structure activity relationships for Sazetidine A analogues. In this application, we present a new class of a4B2 desensitizers called Triazetidines and propose the optimization both in vitro and in vivo. We will also provide gram scale synthetic support for all optimized candidates in vivo behavioral evaluation (project 2) and acute toxicity studies (project 3). This will allow us to establish a therapeutic index for the candidate compounds in this proposal.
Tobacco use and nicotine addiction are an immense public health problem, and the health costs associated with smoking are estimated as $75 billion per year in the U.S. Current treatments for nicotine addiction are not adequate. The goal of this NCDDDG is to develop smoking cessation drugs to help the nearly 50 million people in N. America and 1 billion people worldwide end their addiction to nicotine and stop smoking.
|Dezfuli, Ghazaul; Kellar, Kenneth J; Dretchen, Kenneth L et al. (2016) Evidence for the role of Î²2* nAChR desensitization in regulating body weight in obese mice. Neuropharmacology 110:165-74|
|Forcelli, Patrick A; Turner, Jill R; Lee, Bridgin G et al. (2016) Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology 101:46-56|
|Kong, Hyesik; Song, Jun-ke; Yenugonda, Venkata Mahidhar et al. (2015) Preclinical studies of the potent and selective nicotinic Î±4Î²2 receptor ligand VMY-2-95. Mol Pharm 12:393-402|
|Tuan, Edward W; Horti, Andrew G; Olson, Thao T et al. (2015) AT-1001 Is a Partial Agonist with High Affinity and Selectivity at Human and Rat Î±3Î²4 Nicotinic Cholinergic Receptors. Mol Pharmacol 88:640-9|
|Hussmann, G Patrick; DeDominicis, Kristen E; Turner, Jill R et al. (2014) Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J Neurochem 129:721-31|
|Afshordel, Sarah; Wood, Wellington Gibson; Igbavboa, Urule et al. (2014) Impaired geranylgeranyltransferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain. J Neurochem 129:732-42|
|Liu, Yong; Paige, Mikell; Olson, Thao T et al. (2014) Synthesis and pharmacological characterization of new neuronal nicotinic acetylcholine receptor ligands derived from Sazetidine-A. Bioorg Med Chem Lett 24:2954-6|
|Burke, Dennis A; Heshmati, Pooneh; Kholdebarin, Ehsan et al. (2014) Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats. Eur J Pharmacol 741:132-9|
|Levin, Edward D; Cauley, Marty; Rezvani, Amir H (2013) Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur J Pharmacol 702:269-74|
|Levin, Edward D; Sexton, Hannah G; Gordon, Karen et al. (2013) Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor Î²2-/- and Î±7-/- mice. Eur J Pharmacol 718:167-72|
Showing the most recent 10 out of 21 publications